In The Lupus Atherosclerosis Prevention Study (LAPS) [88], 40 mg/day atorvastatin slowed not significantly atherosclerosis progression, but CRP decreased in the placebo group, more than in the atorvastatin group, which may be a crucial confounder. The gene discussed is CRP; the disease is atherosclerosis.